About Pasithea
Pasithea is a company based in Miami Beach (United States) founded in 2020 by Lawrence Steinman. It operates as a HealthTech. Pasithea has raised $1.46 million across 3 funding rounds. The company has 4 employees as of December 31, 2024. Pasithea has completed 2 acquisitions, including Allomek Therapeutics and Alpha-5 Integrin. Pasithea offers products and services including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy. Pasithea operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Miami Beach, United States
- Employees 4 as on 31 Dec, 2024
- Founders Lawrence Steinman
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pasithea Therapeutics Corp.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-13.9 M12.89as on Dec 31, 2024
-
EBITDA
$-13.6 M11.28as on Dec 31, 2024
-
Total Equity Funding
$1.46 M (USD)
in 3 rounds
-
Latest Funding Round
$30.4 M (USD), Post-IPO
Nov 24, 2021
-
Investors
-
Employee Count
4
as on Dec 31, 2024
-
Investments & Acquisitions
Allomek Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pasithea
Pasithea is a publicly listed company on the NASDAQ with ticker symbol KTTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pasithea
Pasithea offers a comprehensive portfolio of products and services, including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for Neurofibromatosis Type 1 is being developed.
Therapy for ALS is researched for muscle control loss.
Therapy for Multiple Sclerosis is developed for neurodegenerative issues.
Therapy for schizophrenia is explored for psychiatric treatment needs.
Funding Insights of Pasithea
Pasithea has successfully raised a total of $1.46M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.4 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $30.4M
-
First Round
First Round
(26 Jan 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Post-IPO - Pasithea | Valuation |
investors |
|
| Mar, 2021 | Amount | Series A - Pasithea | Valuation |
investors |
|
| Jan, 2021 | Amount | Seed - Pasithea | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Pasithea
Pasithea has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Allomek Therapeutics and Alpha-5 Integrin. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Targeted small molecule therapeutics for cancer are developed.
|
2010 | ||||
|
Monoclonal antibodies are developed for treating neurological disorders.
|
0 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Pasithea
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pasithea Comparisons
Competitors of Pasithea
Pasithea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pasithea
Frequently Asked Questions about Pasithea
When was Pasithea founded?
Pasithea was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Pasithea located?
Pasithea is headquartered in Miami Beach, United States. It is registered at Miami Beach, Florida, United States.
Who is the current CEO of Pasithea?
Tiago Reis Marques is the current CEO of Pasithea.
Is Pasithea a funded company?
Pasithea is a funded company, having raised a total of $1.46M across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Jan 26, 2021.
How many employees does Pasithea have?
As of Dec 31, 2024, the latest employee count at Pasithea is 4.
What does Pasithea do?
Pasithea, a biotechnology company, is engaged in the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company is dedicated to creating therapeutics for conditions such as Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and schizophrenia. Research efforts are concentrated on addressing unmet medical needs in these areas, targeting both benign and cancerous tumors, neurodegenerative diseases, and psychiatric illnesses. Solutions are being developed to improve patient outcomes across these critical health sectors.
Who are the top competitors of Pasithea?
Pasithea's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
What products or services does Pasithea offer?
Pasithea offers Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy.
Is Pasithea publicly traded?
Yes, Pasithea is publicly traded on NASDAQ under the ticker symbol KTTA.
How many acquisitions has Pasithea made?
Pasithea has made 2 acquisitions, including Allomek Therapeutics, and Alpha-5 Integrin.
What is Pasithea's ticker symbol?
The ticker symbol of Pasithea is KTTA on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.